Hong Zebger-Gong
Seminars
Monday 8th March 2027
Evaluating Phase II/III Efficacy & Safety Insights from an ADC in EGFR-Mutated NSCLC
12:00 pm
- Reviewing combined phase II and III efficacy and safety data supporting accelerated approval of the ADC in EGFR-mutated NSCLC
- Exploring key learnings on toxicity management and therapeutic index optimisation drawn from early-phase through late-phase development of the program
- Outlining key safety parameters to take forward in late-stage trials
Monday 8th March 2027
Panel Discussion: Dual Payload & Novel ADCs – Balancing Enhanced Efficacy Against Overlapping Toxicities & Strategies for Effective Translation in Models & in the Clinic
1:30 pm
- How can multiple payloads overcome tumour heterogeneity, resistance, and enhance anti-tumour efficacy?
- Discussing the strategies to mitigate overlapping toxicities, optimise therapeutic windows, and balance increased potency with safety profiles through development
- Examining how preclinical models, biomarker strategies, and translational approaches can better predict clinical outcomes and support the successful development of advanced ADC formats in the clinic
